These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10172485)

  • 1. Economic evaluation of drugs and its potential uses in policy making.
    Johannesson M
    Pharmacoeconomics; 1995 Sep; 8(3):190-8. PubMed ID: 10172485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of health care and policymaking.
    Johannesson M
    Health Policy; 1995 Sep; 33(3):179-90. PubMed ID: 10145120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
    Hoomans T; Severens JL; van der Roer N; Delwel GO
    Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
    Franken M; Koopmanschap M; Steenhoek A
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?
    Anell A; Persson U
    Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of economic evaluation in decision making: evidence and recommendations for improvement.
    Simoens S
    Drugs; 2010 Oct; 70(15):1917-26. PubMed ID: 20883050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporating economic evaluations into decision-making: the Ontario experience.
    Laupacis A
    Med Care; 2005 Jul; 43(7 Suppl):15-9. PubMed ID: 16056004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of health economic information by reimbursement authorities.
    Drummond MF
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii60-3. PubMed ID: 14585919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making a case for employing a societal perspective in the evaluation of Medicaid prescription drug interventions.
    Roy S; Madhavan SS
    Pharmacoeconomics; 2008; 26(4):281-96. PubMed ID: 18370564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?
    Hill S; Freemantle N
    Pharmacoeconomics; 2003; 21(11):761-7. PubMed ID: 12859218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
    Henry D
    Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reimbursable drug classes and ceilings in Italy: why not only one?
    Garattini L; Curto A; Padula A
    Eur J Health Econ; 2016 Nov; 17(8):923-926. PubMed ID: 27255742
    [No Abstract]   [Full Text] [Related]  

  • 15. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
    Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
    Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions?
    Sculpher MJ; Drummond MF
    Pharmacoeconomics; 2006; 24(11):1087-99. PubMed ID: 17067194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why is the pharmaceutical industry investing increasing amounts in health economic evaluations?
    Andersson F
    Int J Technol Assess Health Care; 1995; 11(4):750-61. PubMed ID: 8567207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of pharmacoeconomics in the research and development decision-making process.
    DiMasi JA; Caglarcan E; Wood-Armany M
    Pharmacoeconomics; 2001; 19(7):753-66. PubMed ID: 11548911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.